Ken Fisher
ABCL icon

Ken Fisher’s AbCellera Biologics ABCL Stock Holding History

Ken Fisher’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-273
Closed -$1.76K – 1168
2023
Q2 		$1.76K Hold
273
– – ﹤0.01% 1153
2023
Q1 		$2.06K Buy
+273
New +$2.48K ﹤0.01% 1105

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ken Fisher's ABCL Position: Q3 2023 in Review

Ken Fisher sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 273 shares — an estimated $1.76K sold.

Ken Fisher first reported a position in ABCL in Q1 2023 and held it in 2 quarters. The position peaked at $2.06K in Q1 2023. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • Ken Fisher reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • Ken Fisher sold 273 AbCellera Biologics shares in Q3 2023, an estimated $1.76K.
  • Ken Fisher first reported a position in AbCellera Biologics in Q1 2023 and held it in 2 quarters.
  • Ken Fisher's AbCellera Biologics position peaked at $2.06K in Q1 2023.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on Fisher Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.